Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
暂无分享,去创建一个
Philippe Flandre | Françoise Brun-Vézinet | Diane Descamps | Jean-Pierre Aboulker | G. Peytavin | D. Descamps | P. Yeni | Gilles Peytavin | V. Joly | S. Lastère | Vincent Meiffrédy | Patrick Yeni | P. Flandre | Véronique Joly | Séverine Delarue | Stéphane Lastère | J. Aboulker | S. Delarue | V. Meiffrédy | F. Brun-vezinet
[1] D. Kuritzkes. Drug Resistance Testing: Time to be Used in Clinical Practice? , 2001 .
[2] R. Harrigan,et al. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies , 2000, AIDS.
[3] R. Shafer,et al. Drug resistance mutations in HIV-1. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[4] F. Brun-Vézinet,et al. Efficacy of Zidovudine Compared to Stavudine, Both in Combination with Lamivudine and Indinavir, in Human Immunodeficiency Virus-Infected Nucleoside-Experienced Patients with No Prior Exposure to Lamivudine, Stavudine, or Protease Inhibitors (Novavir Trial) , 2002, Antimicrobial Agents and Chemotherapy.
[5] V. Calvez,et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). , 2000, JAMA.
[6] J. Mellors,et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.
[7] R. Farinotti,et al. Determination of nelfinavir, a potent HIV protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode-array detection. , 1999, Journal of chromatography. B, Biomedical sciences and applications.
[8] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[9] S. Paulous,et al. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. , 1999, AIDS.
[10] E. Woolf,et al. Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. , 1995, Journal of chromatography. A.
[11] R. Elston,et al. Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.
[12] M. Hirsch,et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.
[13] C. Pasquier,et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. , 2001, Journal of Virological Methods.
[14] Victoria A Johnson,et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] V. Soriano,et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir , 2001, AIDS.
[16] M. Mouroux,et al. Early Virological Failure in Naive Human Immunodeficiency Virus Patients Receiving Saquinavir (Soft Gel Capsule)-Stavudine-Zalcitabine (MIKADO Trial) Is Not Associated with Mutations Conferring Viral Resistance , 2000, Journal of Clinical Microbiology.
[17] D. Ho,et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.
[18] S. Yerly,et al. Drug Resistance Mutations in HIV-1-Infected Subjects during Protease Inhibitor-Containing Highly Active Antiretroviral Therapy with Nelfinavir or Indinavir , 2000, Antiviral therapy.